



BOX AF

RESPONSE UNDER 37 CFR 1.116  
EXPEDITED PROCEDURE  
EXAMINING GROUP 1644

TECH CTR 1600/2900

AF  
(Box seq)  
RECEIVED  
SEP 17 2002  
#34/I  
gnd  
09/18/02  
H.E.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Office of  
43  
10-9-02

In re Application of:

Dolores J. SCHENDEL

Group Art Unit: 1644

Serial No. 08/881,509

Examiner: A. DeCloux

Filed: June 24, 1997

Atty. Dkt No. 100564-07015

For: T CELLS SPECIFIC FOR KIDNEY CARCINOMA

AMENDMENT AFTER FINAL REJECTION

**Box AF**

Commissioner for Patents  
Washington, D.C. 20231

September 13, 2002

Sir:

In response to the Office Action dated June 13, 2002, please amend the above-identified application as set forth below.

IN THE SPECIFICATION:

Please delete pages 1-19 at the end of the application containing the Sequence Listing and insert new pages 1-22 containing the revised Sequence Listing at the end of the application.

IN THE CLAIMS:

Please amend claims 2, 4, 5, 7, 26 and 45-46.

2. (Four Times Amended). An isolated nucleic acid which codes for the  $\alpha$  chain of a human T cell receptor, a single chain T cell receptor or a soluble T cell receptor fragment and comprises a CDR3 region selected from the group consisting of: